Ferguson Wellman Capital Management Inc. Has $102.76 Million Position in Amgen Inc. $AMGN

Ferguson Wellman Capital Management Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 313,938 shares of the medical research company’s stock after acquiring an additional 6,372 shares during the quarter. Amgen accounts for about 1.6% of Ferguson Wellman Capital Management Inc.’s investment portfolio, making the stock its 18th biggest position. Ferguson Wellman Capital Management Inc. owned about 0.06% of Amgen worth $102,755,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Amgen during the second quarter valued at approximately $1,663,726,000. Capital World Investors lifted its position in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the period. National Bank of Canada FI lifted its position in shares of Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp boosted its stake in Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after buying an additional 567,400 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its position in Amgen by 367.4% in the second quarter. Panagora Asset Management Inc. now owns 490,457 shares of the medical research company’s stock valued at $136,940,000 after acquiring an additional 385,517 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $353.93 on Thursday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The stock has a market capitalization of $190.79 billion, a PE ratio of 24.87, a PEG ratio of 3.46 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock’s fifty day moving average is $361.76 and its 200-day moving average is $329.23.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s payout ratio is currently 70.84%.

Analyst Ratings Changes

Several research firms have issued reports on AMGN. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Wells Fargo & Company upped their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a research report on Tuesday, January 20th. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Finally, Leerink Partners restated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.